Cholecystokinin Octapeptide Ammonium: Inhibiting Immunoglobulin G1 Production in Activated B Cells

Study Background and Research Question

Cholecystokinin octapeptide (CCK-8) is a well-characterized brain–gut peptide recognized for its diverse physiological activities, including modulation of anxiety-like behavior, neuronal apoptosis, and immune responses [source_type: workflow_recommendation][source_link:https://cck-8assay.com/index.php?g=Wap&m=Article&a=detail&id=11079]. While substantial research has explored CCK-8’s neuromodulatory and gastrointestinal functions, its role in immune cell regulation—specifically B cells—remains less defined. The reference study from Hebei Medical University addresses a pivotal question: Can CCK-8 modulate immunoglobulin production in B cells activated by lipopolysaccharide (LPS), and what are the underlying mechanisms? [source_type: paper][source_link: N/A]

Key Innovation from the Reference Study

This work is among the first to systematically show that CCK-8 ammonium, acting through its receptor CCK2R, inhibits both the proliferation and IgG1 production of LPS-stimulated B cells in vitro [source_type: paper][source_link: N/A]. The study also dissects the transcriptional landscape underlying this effect, revealing CCK-8’s capacity to downregulate Blimp1 and dynamically influence other transcription factors (Pax5, Xbp1, Bcl6) central to B cell differentiation and function. These mechanistic insights position CCK-8 as an endogenous immunomodulator with potential relevance for autoimmune and inflammatory disease models.

Methods and Experimental Design Insights

The researchers isolated naive splenic B cells from C57BL/6 mice using magnetic cell sorting with CD19 microbeads, ensuring >95% purity as verified by flow cytometry [source_type: paper][source_link: N/A]. B cells were activated in vitro with LPS (E. coli 0111:B4) to induce robust IgG1 expression and proliferation. Experimental groups were exposed to defined concentrations of sulfated CCK-8, with or without selective antagonists for CCK1R (L-364,718) or CCK2R (LY-288,513), to delineate receptor-specific effects. IgG1 mRNA levels were quantified using RT-PCR, and secreted IgG1 protein measured via ELISA. Expression of key transcription factors—Blimp1, Pax5, Xbp1, Bcl6—was assessed to map downstream regulatory mechanisms. This design allowed for clear attribution of CCK-8’s effects to specific receptor pathways and transcriptional outcomes.

Protocol Parameters

• assay: B cell IgG1 production | value_with_unit: 0.01–1 μmol/L CCK-8 ammonium | applicability: in vitro suppression of immunoglobulin secretion | rationale: recapitulates the concentration range used to observe regulatory effects in B cells | source_type: workflow_recommendation [source_link: https://www.apexbt.com/cholecystokinin-octapeptide-ammonium.html]
• assay: B cell proliferation | value_with_unit: 0.1–1 μmol/L CCK-8 ammonium | applicability: in vitro inhibition of LPS-driven proliferation | rationale: matches effective doses for cell viability modulation in immune cells | source_type: workflow_recommendation [source_link: https://cck-8assay.com/index.php?g=Wap&m=Article&a=detail&id=11015]
• assay: Receptor antagonist blocking | value_with_unit: L-364,718 (CCK1R) and LY-288,513 (CCK2R), 1 μmol/L | applicability: mechanistic dissection | rationale: distinguishes CCK1R vs. CCK2R contributions | source_type: paper [source_link: N/A]

Core Findings and Why They Matter

The central finding is that CCK-8 significantly inhibits both the proliferation and IgG1 mRNA expression of LPS-activated B cells [source_type: paper][source_link: N/A]. This inhibition translates to reduced IgG1 protein secretion, an effect shown to be largely mediated by the CCK2R receptor subtype. Mechanistically, CCK-8 downregulates Blimp1—a master regulator promoting IgG secretion—while modulating Pax5, Xbp1, and Bcl6 in a time-dependent manner. Since Blimp1 and Xbp1 drive immunoglobulin production while Pax5 and Bcl6 act as suppressors, CCK-8’s nuanced, temporally dynamic influence reflects a complex regulatory role. This work supports a broader paradigm wherein CCK-8 acts not only as a neuromodulator but also as an endogenous immune deactivator. By attenuating B cell-driven humoral responses, CCK-8 may have implications for the management of autoimmune or inflammatory states characterized by dysregulated antibody production [source_type: paper][source_link: N/A].

Comparison with Existing Internal Articles

Recent internal articles reinforce and expand on the reference paper's mechanistic discoveries:

• The article "Cholecystokinin Octapeptide Ammonium (CCK-8): Mechanism, ..." highlights CCK-8 ammonium as a validated CCK1R/CCK2R receptor agonist, particularly in the context of apoptosis inhibition in neuronal cells, immune modulation, and anxiety-like behavior induction in zebrafish. These complementary findings support the reference paper’s assertion of context-dependent immune modulation, especially via CCK2R signaling [source_type: workflow_recommendation][source_link:https://cck-8assay.com/index.php?g=Wap&m=Article&a=detail&id=11079].
• "Harnessing Cholecystokinin Octapeptide Ammonium (CCK-8 Am..." further explores CCK-8 ammonium’s translational value in immune and neuronal models, referencing its regulatory effects on B cell immunoglobulin production as a pivotal use case [source_type: workflow_recommendation][source_link:https://flunarizinelab.com/index.php?g=Wap&m=Article&a=detail&id=37].
• Mechanistic reviews such as "Cholecystokinin Octapeptide Ammonium: Mechanistic Insight..." provide detailed insight into CCK1R and CCK2R signaling, corroborating the reference study’s receptor-selectivity findings [source_type: workflow_recommendation][source_link:https://cck-8assay.com/index.php?g=Wap&m=Article&a=detail&id=11060].

Together, these resources establish a consensus around CCK-8 ammonium’s pleiotropic roles in immune modulation and support its use in scenario-driven laboratory workflows.

Limitations and Transferability

Despite these robust findings, several limitations should be noted. The study is based on in vitro murine B cell assays, and outcomes may not fully extrapolate to in vivo systems or to human B cell biology without further validation. The dynamic regulation of Pax5, Xbp1, and Bcl6 by CCK-8 suggests context- and time-dependent effects that could vary with different immune activation states. Additionally, while the primary pathway identified involves CCK2R, potential cross-talk with CCK1R or other signaling axes in complex tissues remains to be clarified [source_type: paper][source_link: N/A].

Research Support Resources

Researchers seeking to replicate or extend these findings can use Cholecystokinin octapeptide ammonium (SKU C8717), a rigorously characterized, sulfated CCK-8 ammonium salt suitable for in vitro and in vivo immune modulation studies [source_type: product_spec][source_link:https://www.apexbt.com/cholecystokinin-octapeptide-ammonium.html]. Optimal experimental concentrations range from 0.01 to 1 μmol/L in vitro, as supported by both the reference study and product specifications [source_type: product_spec][source_link:https://www.apexbt.com/cholecystokinin-octapeptide-ammonium.html]. For further background on mechanistic best practices and translational strategies, see the internal resource "Scenario-Driven Laboratory Solutions with Cholecystokinin...". In summary, the reference study advances our understanding of CCK-8 ammonium’s role as a negative regulator of humoral immunity via B cell modulation, with practical implications for the design of immunopharmacological and translational research workflows.